GCT to Conduct a Rare Pulmonary Disease Study
GCT has been awarded a new clinical trial in Ukraine and Russia. A Phase II multinational study in subjects with Idiopathic Pulmonary Fibrosis (IPF) is designed to investigate the safety, efficacy, and pharmacokinetics of the investigational product.
July 7, 2020
Multinational Natural History Rare Disease Study Extension
GCT is awarded to run the rare disease project globally. The trial is already ongoing and managed by GCT in India. In addition to that, the sites will now open in Western and Mediterranean Europe, Western Asia, and Great Britain. GCT is providing regulatory, clinical trial management, EU Legal representation and GDPR support for this study.
The indication under research is an extremely rare genetic disease inherited as an autosomal recessive trait.
June 25, 2020
COVID-19 study to be conducted in Russia and Ukraine
Global Clinical Trials has been awarded a randomized, double-blind, placebo-controlled phase II clinical study in patients with COVID-19, SARS CoV-2 infection. GCT will manage project in Ukraine and Russia targeting to enroll about 50 hospitalized subjects in 1,5 months. The objective of the trial it to evaluate the drug safety and its effect on inflammation.
June 24, 2020
GCT supports the White Nights Ophthalmology Congress going virtual
For over a decade GCT has been the Exclusive Information Partner of the Congress, running the Congress website, providing organization and participant registration services. This year, due to the global pandemic, the congress has been held as a hybrid event, with the participant numbers reaching over 5,400. GCT is proud to support the Congress in these challenging circumstances.
June 2, 2020
Meet our clients
All trademarks, brand names and logotypes are intellectual property of their respective owners.
Pennsylvania Convention Center
Philadelphia, PA, USA
2020, September 09—11